CureBay Raises 100 Crore to Take Rural Clinics to More Indian States

Rural clinics get a 100 crore vote of confidence

CureBay raised about 100 crore rupees (roughly 11 million dollars) in a pre-Series C round announced on October 22, 2026, to expand its network of rural clinics across India. IvyCap Ventures led the round, which included about 69 crore in equity plus more than 30 crore in debt from Trifecta Capital, Alteria Capital, and VentureSoul Partners. The money will fund expansion into new states, including Andhra Pradesh, and improvements to CureBay's AI health screening.

Founded in 2021 by Priyadarshi Mohapatra, Shobhan Mahapatra, and Sanjay Swain, CureBay runs tech-enabled clinics in rural and underserved areas. Its clinics offer doctor consultations, medicines, diagnostic tests, and help arranging surgery. The company says it now operates more than 250 clinics across seven states and has served over 1.7 million patients. Those are the numbers that make this round interesting: this is not a pitch deck promise, it is an operating network adding new territory.

Why rural clinics are hard to scale

Rural healthcare in India is a distribution problem before it is a technology problem. Doctors cluster in cities, diagnostic labs need volume to survive, and patients often travel hours for care they could get locally if the clinic existed. CureBay's model tries to solve the distribution part first: put a physical clinic in the community, staff it, connect it to doctors and diagnostics remotely where needed, and keep medicines in stock on site.

The AI screening piece deserves a careful read. Screening tools can help a small clinic catch warning signs earlier, but they only help if the follow-up exists: a referral, a test, a doctor who acts on the result. CureBay's pitch is that its clinics provide that follow-up in the same place, rather than handing a patient a report and a bus ticket. Investors betting 100 crore are betting that the full loop, not just the algorithm, is what scales.

What the funding round says about healthtech in 2026

Healthtech funding has cooled from its pandemic peak, and rounds now favor companies with revenue, clinics, and patients rather than apps with downloads. CureBay fits that shift. Compare it with the legal AI arms race, where Legora raised 550 million dollars at an 8.8 billion valuation, or the physical-world AI bet behind ASI's 325 million dollar Series C. CureBay's round is smaller and quieter, but it is tied to a service people use in person, which is a different kind of durability.

The debt portion of the round is also telling. Mixing equity with debt is common when a company has predictable clinic economics and wants to fund expansion without giving away too much ownership. It also adds pressure: debt has to be repaid whether the new clinics ramp fast or slow. Watch CureBay's clinic count and state expansion over the next year for the real test of this round.

What to watch next

Three things matter from here. First, whether the Andhra Pradesh expansion and other new states reach the same patient volumes as the existing seven. Second, whether AI screening improves outcomes measurably, not just throughput, because regulators and patients will eventually ask for proof. Third, whether CureBay can keep quality consistent across 250 plus clinics, since one bad clinic damages trust in the whole network faster than any marketing can repair.

For patients in the towns CureBay serves, the abstract funding news translates to something concrete: a clinic closer to home, with a doctor, medicines, and tests in one place. That is a modest promise, and it is exactly why it might work.